CTIS2024-512908-19-00进行中（未招募）1 期
BLCL-LEN-EU-01
Bluepharma Industria Farmaceutica S.A.0 个研究点目标入组 30 人开始时间: 2024年6月5日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
Bioequivalence of Tofacitinib 10 mg Film-Coated Tablets in Healthy Subjects Under Fasting Conditions.CTIS2023-504516-15-00Bluepharma Industria Farmaceutica S.A.38
进行中（未招募）
1 期
Comparative Bioavailability of Lenvatinib 10 mg Capsules in Healthy SubjectsAdvanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery or radiation., Progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hurthle cell) thyroid carcinoma, refractory to radioactive iodine in adults., Advanced or unresectable hepatocellular carcinoma in adults who have received no prior systemic therapy.MedDRA version: 21.1Level: LLTClassification code: 10049010Term: Carcinoma hepatocellular Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10014743Term: Endometrial carcinoma Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10007476Term: Carcinoma thyroid Class: 10029104CTIS2022-501327-25-00Bluepharma Industria Farmaceutica S.A.36
进行中（未招募）
1 期
Bioequivalence of Betis®10 mg Film-Coated Tablets versus Clozan 10 mg tablets in Healthy Subjectso medical condition.CTIS2023-504901-34-00Synthon Chile LTDA.30
进行中（未招募）
1 期
Comparative Bioavailability of Lisdexamfetamine Dimesylate 70 mg in Healthy Subjects Under Fasting Conditionso medical condition.CTIS2023-509808-15-00Pharmaplot P.C.12
进行中（未招募）
1 期
Comparative Bioavailability of Empagliflozin 25 mg Film-Coated Tablets: A Single-Dose, Open-Label, Randomized, Two-Sequence, Two-Treatment, Two-Period Crossover Study in Healthy Subjects Under Fasting Conditions.o medical conditionCTIS2023-506416-41-00Tecnimede-Sociedade Tecnico-Medicinal S.A.16